Krista works with pharmaceutical and biotech companies to find design-effective commercialization solutions.
With more than 20 years of experience in the pharmaceutical industry, Krista is an experienced sales representative and district manager, with strong client management, business development, and global account experience. Her work in clinical research, trials and development, as well as product launch experience, has been employed across numerous therapeutic areas including cardiology, oncology, neurology and urology.
Krista was recognized by the Healthcare Businesswoman’s Association as a Rising Star in 2012 and by both inVentiv Health and Alamo Pharma Services for her leadership, business results, and customer service. She holds a bachelor’s degree in science, communications and business ethics from the University of Delaware.
Articles by Krista Pinto
Invisible Orchestration: How Behind-the-Scenes Collaboration of Patient Services and Field Deployment Teams Delivers a Seamless Front-of-House Brand Experience
Providing services to patients in a digital world requires a delicate balance of blending high-tech and high-touch solutions. A majority of patients want the option to guide their own treatment journeys with ease and on their own time as much as possible. But they also want the ability to speak directly with experts concerning more complex issues such as benefit requirements and affordability options. Manufacturers’ primary objective is to ensure patients receive the highest level of care in a timely fashion and properly adhere to their prescribed therapies for as long as needed. To achieve this, they must implement strategical thinking that supports staying abreast of the latest trends and technological […]
Leveraging Salesforce Marketing Cloud Personalization to Power the Next Generation Rep
Life sciences companies need to shift from the mindset of a pharmaceutical manufacturer of the twentieth, to that of the digital healthcare company of the twenty-first. Reps remain important, but they need to be empowered to succeed. The tools they were given in a slower-paced, less complex paradigm are no longer enough. Research has shown that reps empowered to have hybrid digital and in-person conversations improve cost efficiency by 80%, surpassing the combined sales growth of the two stand-alone segments by 3%. The next-generation rep must cut through volume and noise with relevant, value-based experiences that span 360 degrees over their interactions with the brand, in order to drive influence – because […]
Reigniting Revenue for Established Brands
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease in utilization and patient access due to the pandemic, making them vulnerable to negative financial impacts that are difficult to rebound from. For example, we analyzed a sample of these brands to understand the financial impact they experienced during the COVID-19 pandemic. The results indicated a massive revenue reduction that cost these brands over $3.9B of revenue over a nine-month time frame. Manufacturers have several options available to change the trajectory and maximize the […]
Reignite Established Brands — Actual Use Case
EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established brands experienced a 1:3 to 3:6 return on investment ratios. This critical ROI observation illustrates how established brands have the opportunity to change the trajectory of these product portfolios and maximize value, utilizing resources already dedicated to the brand. Read the complete white paper on Reigniting Value in Established Brands.
Is Your Salesforce Keeping Up With Rapidly Evolving HCP Preferences?
Krista Pinto, President, Deployment Solutions, participated in a panel alongside industry leaders at Reuters Events: Pharma USA 2022. The discussion analyzed how pharmaceutical salesforces must progress in tandem with rapidly evolving healthcare providers (HCPs) and illustrated EVERSANA’s unique ability to build efficient, future-focused field models that overcome market challenges. The onset of COVID-19 provided an opportunity to reassess the industry’s standard working model and establish more efficient interactions with HCPs. EVERSANA sought to better understand pandemic pressures placed on HCPs and the results of their experiences over the last two years. Three distinct phases were identified: Phase 1: Severe Contraction – COVID catalyzed an abrupt halt to and contraction of […]
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical industry has proven that it can adapt to change. In 2020, pharma pivoted to manage the coronavirus pandemic, and in 2021 the industry was met with the resounding need to keep pushing, keep evolving – so it did. While some change was overdue, such as streamlining outdated processes with leading technologies, other changes were radical and transformative. In the past two years, changing market conditions have forced pharma to consider new strategies, resulting in […]
The Power to Know When: Balancing High-Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers
Forty percent of consumers prefer speaking to a real person on the phone, and for more complex issues, 80% want to speak to a live service agent. In the increasingly virtual world we live in, one thing remains clear: we still crave human interactions. As a result, pharma manufacturers need to understand how patients and providers are consuming information, connecting with others, and completing daily tasks. In solving for access, affordability and adherence barriers, they need to adopt a new equation that combines the forces of high-tech and high-touch solutions to: Create a cohesive brand experience, Ensure maximum impact, and Drive therapy adoption. Download the article to discover EVERSANA’s recommended […]
Ask the Expert: One-on-One with Krista Pinto
Forty percent of worldwide drug launches between 2009 and 2017 failed to meet their two-year sales forecasts. Manufacturers can’t afford to overlook the full potential of a data-driven omnichannel strategy. Omnichannel success requires a comprehensive suite of pivotal datasets and a data-driven technology model that provides real-time visibility into the impact of sales calls and marketing efforts. EVERSANA commercialization expert Krista Pinto answers an important question every manufacturer needs to know about omnichannel: How do data-driven, omnichannel insights drive brand success? Additional Reading Download Krista Pinto and Amy Hutnik’s latest article to learn how to leverage a best-in-class omnichannel activation model that drives performance and profitability.
Omnichannel: A Conversation With the Innovators
Go beyond marketing to provide actionable insights that better inform commercial strategies and elevate brand success. EVERSANA’s best-in-class omnichannel activation model aggregates and synthesizes pivotal datasets from marketing campaigns, patient services programs and field activities to analyze and predict trends and behaviors that better inform promotional and support strategies. Serving as a seamless router of actionable data and deep insights from all channels, the platform provides the optimal coordination of customized touch points required to create a seamless brand experience for healthcare providers, patients, payers and other key stakeholders. In this 11-minute one-on-one video conversation with the experts, Krista Pinto and Amy Hutnik explain why manufacturers should expect more from their omnichannel strategy and investments to accelerate […]
Ask the Expert: How to Maximize Your Omnichannel Strategy
Omnichannel strategies are transforming the way consumers interact with brands across industries – from the all-in-one Magic Band experience at Disney to buying your favorite latte with the Starbucks app. The pharmaceutical industry is no exception, constantly evolving and implementing omnichannel strategies to reach patients and providers with truly personalized, timely engagement. But unlike all other industries, pharma is an ecosystem in motion, with manufacturers, providers, payers and other stakeholders doing their part to treat patients and meet their own industry needs. An omnichannel strategy is the key to connecting the pieces of this complex system and simplifying the patient’s journey to treatment adoption, adherence and improved outcomes. Whether you’re […]
Expect More From Your Omnichannel Strategy and Investments
From ordering your daily Starbucks latte on your iPhone to skipping the line at Splash Mountain with your Disney Magic Band, omnichannel strategies transform how consumers interact with their favorite brands. The most successful brands create an immersive experience that meets the needs of their consumers with a personalized touch. Instead of falling for the temptation to “be everywhere,” omnichannel meets consumers where they are to make every engagement count. Recognizing the major advantages of omnichannel thinking, many pharmaceutical manufacturers have started to adopt a similar strategy for their own brands. While manufacturers often disseminate compelling promotional messages across various channels, in many cases message strategy is still confined to […]
The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value
The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their clinical outcomes. The clinical consequences of this will lead to compromised patient outcomes and further healthcare cost increases. This also leads to negative strategic and financial ramifications for biopharma manufacturers who produce these therapies. Billions of dollars of revenue and tens of billions of dollars of market valuation have been erased over the last year due to COVID-related market conditions, for every dollar of revenue lost can lead to a disproportionate loss in market […]
Moving Forward in Pharma: Reigniting Revenue for Mature Brands
The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in a normal market. These brands have historically provided reliable revenue support, allowing manufacturers to research and develop drugs in new treatment areas. Now, approximately $31.4B of these “recurring” revenue stream brands are facing failure due to COVID-19-related impacts. As COVID-19 cuts into pharma’s bottom line, manufacturers need to begin strategizing how they can address the […]
The 2020 Playbook Addendum: Augment Your Frontline to Boost Sales Momentum
In the midst of a global pandemic, the role of commercial field teams evolved right before our eyes. Digital sales aids and tele-detailing are now mandatory sales tactics in a virtual Provider-Rep engagement. Now that field teams are starting to settle into “the new normal,” manufacturers are turning their attention to the next phase: make up lost sales. Fortunately, this initial shift to virtual engagements and supporting infrastructure (e.g., technology) enables manufacturers to complement field promotions with more personalized services for providers and patients. Download Krista Pinto’s latest article to learn how three proven strategies can augment your frontline and boost momentum in: 1) Prescription Volume, 2) Product Affordability, and […]
How to Demonstrate Value to Providers, Payers & Patients
Fact: Primary stakeholders – providers, patients and payers – have greater expectations than ever before. To ensure success at every stage of the product life cycle, it’s imperative to deploy a sophisticated, clinically oriented and data-driven field force who can demonstrate value to all three: Creating value for providers means presenting real-world evidence of positive outcomes Communicating value to payers means proving your product is worth the cost Maximizing value for patients means delivering on promise and exceeding expectations Watch webinar “How to Demonstrate Value to Providers, Payers & Patients“ to learn how your field force can become an integral part of a winning commercial strategy.
Pushing Your Frontline Into A New Frontier
The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to market, but how do brands keep their products positioned appropriately with limited resources, data and time? EVERSANA’s Executive Vice President of Field Solutions, Krista Pinto, reveals a surprising new driver of commercial success and how you can create value at every stage of the product life cycle.